BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32944402)

  • 21. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
    Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
    Roider T; Wang X; Hüttl K; Müller-Tidow C; Klapper W; Rosenwald A; Stewart JP; de Castro DG; Dreger P; Hermine O; Kluin-Nelemans HC; Grabe N; Dreyling M; Pott C; Ott G; Hoster E; Dietrich S
    Int J Cancer; 2021 Jan; 148(1):150-160. PubMed ID: 32638373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib.
    Chaturvedi NK; Hatch ND; Sutton GL; Kling M; Vose JM; Joshi SS
    Leuk Lymphoma; 2019 May; 60(5):1214-1223. PubMed ID: 30424705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4.
    Valentin Hansen S; Høy Hansen M; Cédile O; Møller MB; Haaber J; Abildgaard N; Guldborg Nyvold C
    Sci Rep; 2021 Sep; 11(1):19092. PubMed ID: 34580376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
    Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
    Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.
    Mohanty A; Sandoval N; Das M; Pillai R; Chen L; Chen RW; Amin HM; Wang M; Marcucci G; Weisenburger DD; Rosen ST; Pham LV; Ngo VN
    Oncotarget; 2016 Nov; 7(45):73558-73572. PubMed ID: 27713153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma.
    Jung HJ; Chen Z; McCarty N
    Leuk Lymphoma; 2011 Jun; 52(6):1066-79. PubMed ID: 21599592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
    Jung HJ; Chen Z; Fayad L; Wang M; Romaguera J; Kwak LW; McCarty N
    Exp Hematol; 2012 Feb; 40(2):107-18.e2. PubMed ID: 22024108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK
    Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
    Phillips T; Barr PM; Park SI; Kolibaba K; Caimi PF; Chhabra S; Kingsley EC; Boyd T; Chen R; Carret AS; Gartner EM; Li H; Yu C; Smith DC
    Invest New Drugs; 2019 Apr; 37(2):297-306. PubMed ID: 30132271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel agents for mantle cell lymphoma: molecular rational and clinical data.
    Sarkozy C; Ribrag V
    Expert Opin Investig Drugs; 2020 Jun; 29(6):555-566. PubMed ID: 32321318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
    Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
    Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
    Rudelius M; Rosenfeldt MT; Leich E; Rauert-Wunderlich H; Solimando AG; Beilhack A; Ott G; Rosenwald A
    Haematologica; 2018 Jan; 103(1):116-125. PubMed ID: 29079592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.
    Rolland D; Ribrag V; Haioun C; Ghesquieres H; Jardin F; Bouabdallah R; Franchi P; Briere J; De Kerviler E; Chassagne-Clement C; Raponi M; Houlgatte R; Jais JP; Thieblemont C
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):781-90. PubMed ID: 19960345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
    Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
    Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response.
    Yuan S; Zuo W; Liu T; Fu H
    Technol Cancer Res Treat; 2023; 22():15330338231208608. PubMed ID: 37880950
    [No Abstract]   [Full Text] [Related]  

  • 40. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
    Arkwright R; Pham TM; Zonder JA; Dou QP
    Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.